Blood-Brain Barrier Remains Major Obstacle for Brain Tumor and CNS Therapies

Getting drugs into the brain remains one of the most significant barriers when treating patients with glioblastoma and other central nervous system diseases. The blood-brain barrier, which evolved over approximately 100 million years to protect the brain from foreign molecules, blocks most treatments from reaching tumors.

The barrier surrounds every blood vessel in the brain and prevents many therapies from achieving therapeutic levels. Only about 0.01% of biologic drugs—including antibodies, gene therapies and cellular therapies—actually reach the brain. This creates a difficult tradeoff between affecting the rest of the body and failing to get enough drug into the tumor to reach therapeutic levels.

Small-molecule drugs like temozolomide can cross the barrier to some degree and have been FDA approved for many years. However, these drugs typically slow disease progression rather than stop it. The therapies with the greatest potential for long-term control are biologics, but these face an even greater delivery challenge.

The challenge is not limited to recurrent glioblastoma but applies broadly to diseases of the central nervous system. While researchers understand much about the biology of these conditions and have developed drugs that show strong results in animal models, translating those results to humans has often been limited by drug delivery.

Pharmaceutical companies are increasingly prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization.

Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous system indications are drawing renewed attention. Oncotelic Therapeutics recently announced expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform. The development strengthens protection across neurology, oncology and CNS drug-delivery technologies aimed at crossing the blood-brain barrier.

Central nervous system disorders represent one of the largest and most complex therapeutic areas globally. The World Health Organization reports neurological conditions among the leading causes of disability worldwide, affecting more than one-third of the global population.

Researchers at the University of California, Santa Barbara, have pioneered a groundbreaking approach that significantly streamlines the synthesis of non-natural amino acids. These amino acids are central to constructing peptides but go beyond the standard 22 amino acids naturally encoded in biological systems. Their research, soon to be featured in the Journal of the American Chemical Society, introduces a facile, efficient synthetic strategy that paves the way for unprecedented access to diverse and functionally rich amino acids for peptide assembly.

The new method employs a gold-catalyzed reaction sequence beginning with inexpensive and readily available chemical starting materials. This approach not only maximizes stereoselectivity but also simplifies the purification and preparation phases. The innovative method primes the carboxylic acid group of the generated amino acids for immediate peptide bond formation, circumventing several common synthetic bottlenecks.

The ability to readily include non-natural amino acids within peptides equips drug developers with the tools to significantly enhance therapeutic efficacy. Peptide therapeutics have garnered significant attention for their transformative impact on treating complex health conditions such as obesity and diabetes, with drugs like Ozempic demonstrating the efficacy of peptide-based treatments.